2. Search Result
Search Result
Results for "

cardiovascular and cerebrovascular diseases

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

3

Screening Libraries

1

Biochemical Assay Reagents

1

Peptides

15

Natural
Products

3

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N1362
    Salvianolic acid B
    Maximum Cited Publications
    20 Publications Verification

    Lithospermic acid B

    		 Autophagy Cardiovascular Disease
    Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
    Salvianolic acid B
  • HY-N1913
    Danshensu
    5+ Cited Publications

    Dan shen suan A; Salvianic acid A

    		 Keap1-Nrf2 NF-κB Reactive Oxygen Species (ROS) SARS-CoV Apoptosis Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Danshensu (Dan shen suan A), an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research .
    Danshensu
  • HY-NP165
    Advanced glycation end products

    AGEs

    		 Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Advanced glycation end products (AGEs) are a series of stable compounds generated through non-enzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. Advanced glycation end products are often used as targets to evaluate the inhibitory effects of anti-glycation compounds. Advanced glycation end products can be applied to research on diabetes, cardiovascular and cerebrovascular diseases, inflammation, aging, and other conditions .
    Advanced glycation end products
  • HY-B0531
    Triflusal

    		COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
    Triflusal
  • HY-N2127
    Pinostrobin
    3 Publications Verification

    		 Amyloid-β Apoptosis Ser/Thr Protease HSV Interleukin Related Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Pinostrobin is a flavonoid with anti-cancer, antioxidant, antiviral and neuroprotective activities. Pinostrobin has oral activity. Pinostrobin is a potent PCSK9 inhibitor that inhibits the catalytic activity of PCSK9. Pinostrobin can be used in the research of viral infections, cancer, leukemia, cardiovascular and cerebrovascular diseases, cirrhosis, inflammation and neurological diseases .
    Pinostrobin
  • HY-W506116
    Ostruthin

    Ostruthine

    		 Bacterial DNA/RNA Synthesis Cardiovascular Disease Infection
    Ostruthin is a natural coumarin compound with bacterial and antimycobacterial activities . Ostruthin inhibits the growth of mycobacteria and Staphylococcus aureus. Ostruthin suppresses vascular smooth muscle cell proliferation as well as de novo cellular DNA synthesis. Ostruthin is applicable to research related to mycobacterial infections and cardiovascular and cerebrovascular diseases .
    Ostruthin
  • HY-128393
    Trilinolein
    1 Publications Verification

    		 PI3K Akt E-Selectin Apoptosis MMP MEK ERK Cancer
    Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .
    Trilinolein
  • HY-148837
    GT19630

    		PROTACs c-Myc Casein Kinase Infection Cardiovascular Disease Cancer
    PROTAC c-Myc degrader-1 (Compound A153) is a multiple target protein degrader (PROTAC). PROTAC c-Myc degrader-1 effective degrades c-MYC, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. PROTAC c-Myc degrader-1 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection (Pink: c-Myc ligand (HY-168685); Blue: E3 ligase ligand (HY-W093472); Black: linker (HY-W015808)) .
    GT19630
  • HY-P5381
    gp91 ds-tat
    1 Publications Verification

    		 NADPH Oxidase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase TRP Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    gp91 ds-tat, a biological active peptide, is a NADPH oxidase 2 (Nox2) inhibitor. gp91 ds-tat blocks NADPH oxidase-dependent superoxide production. gp91 ds-tat ameliorates high glucose-induced increase in total ROS, LPOs and iron levels. gp91 ds-tat inhibits homocysteine (Hcy)-induced activation of NLRP3 inflammasomes and restores Hcy-inhibited lysosomal TRPML1 channel activity. gp91 ds-tat improves cerebrovascular and cognitive function in APP/PS1 mice. gp91 ds-tat can be used for the study of Alzheimer’s disease (AD), glomerular inflammation and cardiovascular disease .
    gp91 ds-tat
  • HY-N1775
    3',4'-Dihydroxyacetophenone

    3,4-DHAP

    		 Tyrosinase Reactive Oxygen Species (ROS) Keap1-Nrf2 PARP Autophagy Apoptosis Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    3',4'-Dihydroxyacetophenone (3,4-DHAP) is a phenolic compound with oral bioavailability, possessing potent antioxidant, anti-inflammatory, anticancer and cardiovascular protective activities. 3',4'-Dihydroxyacetophenone inhibits mushroom Tyrosinase activity with an IC50 of 10 μM, thereby suppressing melanogenesis . 3',4'-Dihydroxyacetophenone inhibits platelet aggregation in platelet-rich plasma. 3',4'-Dihydroxyacetophenone reduces ROS levels in human umbilical vein endothelial cells treated with high glucose, upregulates the expression of Nrf2, HO-1 and PARP-1 in cells, and promotes the nuclear translocation of Nrf2 . 3',4'-Dihydroxyacetophenone induces autophagy and apoptosis. 3',4'-Dihydroxyacetophenone inhibits seed germination/growth in most plants. 3',4'-Dihydroxyacetophenone can be used in the research of cancer, neurodegenerative diseases, non-alcoholic steatohepatitis, diabetes, obesity, skin pigmentation disorders, and cardiovascular and cerebrovascular diseases .
    3',4'-Dihydroxyacetophenone
  • HY-100634
    4-Hydroxypropranolol hydrochloride

    (±)-4-hydroxy Propranolol hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    4-Hydroxypropranolol hydrochloride is a non-cardiac selective β-adrenergic receptor antagonist and a metabolite produced after oral administration of Propranolol (HY-B0573B). 4-Hydroxypropranolol hydrochloride also acts as a membrane stabilizer and possesses intrinsic sympathomimetic inhibitory activity. 4-Hydroxypropranolol hydrochloride blocks β-adrenergic receptors to antagonize the effects of catecholamines, acts as a partial β-adrenergic receptor agonist, and induces membrane stabilization. 4-Hydroxypropranolol hydrochloride alters heart rate, left ventricular contractility, and atrioventricular conduction time. 4-Hydroxypropranolol hydrochloride can be used in research related to cardiovascular and cerebrovascular diseases .
    4-Hydroxypropranolol hydrochloride
  • HY-100662
    Didesethyl chloroquine

    Bisdesethylchloroquine

    		 Drug Metabolite Cardiovascular Disease Infection
    Didesethyl chloroquine (Bisdesethylchloroquine) is the major metabolite of the antimalarial agent Chloroquine (HY-17589A). Didesethyl chloroquine is a potent myocardial inhibitor. Didesethyl chloroquine reduces calcium binding and accumulation in cardiac mitochondria, induces mitochondrial swelling, rupture and membrane conformational changes. Didesethyl chloroquine inhibits the growth of Plasmodium falciparum strains. Didesethyl chloroquine can be used in research related to malaria, chikungunya virus infection, and cardiovascular and cerebrovascular diseases .
    Didesethyl chloroquine
  • HY-121765
    Dacisteine

    N,S-Diacetyl-L-cysteine

    		 Endogenous Metabolite Metabolic Disease
    Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine
  • HY-107802
    Breviscapine
    2 Publications Verification

    Breviscapinun

    		 NF-κB Interleukin Related TGF-beta/Smad Calcium Channel Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Breviscapine (Breviscapinun) is a flavonoid compound with antioxidant, anti-inflammatory, anti-fibrotic, and neuroprotective activities. Breviscapine ameliorates cerebral ischemia/reperfusion injury and vascular dementia, and inhibits the formation of postoperative abdominal adhesions. The mechanism of action of Breviscapine involves the regulation of oxidative stress, inflammatory cytokines, signaling pathways such as TGF-β/Smad, and cellular calcium overload. Breviscapine is used for research on diseases including cardiovascular and cerebrovascular diseases .
    Breviscapine
  • HY-N1913A
    Danshensu sodium
    5+ Cited Publications

    Dan shen suan A sodium; Salvianic acid A sodium

    		 Keap1-Nrf2 NF-κB Reactive Oxygen Species (ROS) SARS-CoV Apoptosis Infection Cardiovascular Disease Inflammation/Immunology Cancer
    Danshensu (Dan shen suan A) sodium, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu sodium reduces reactive oxygen species (ROS) production, upregulates antioxidant defense mechanism and inhibits intrinsic apoptotic pathway. Danshensu sodium displays a potent antiviral activity against SARS-CoV-2 with EC50 of 0.97 μM. Danshensu sodium has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research .
    Danshensu sodium
  • HY-N1362R
    Salvianolic acid B (Standard)

    Lithospermic acid B (Standard)

    		 Reference Standards Autophagy Cardiovascular Disease
    Salvianolic acid B (Standard) is the analytical standard of Salvianolic acid B. This product is intended for research and analytical applications. Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
    Salvianolic acid B (Standard)
  • HY-113145
    (Rac)-Salvianic acid A

    (Rac)-Danshensu; (Rac)-Tanshinol

    		 Drug Isomer Others
    (Rac)-Salvianic acid A is the racemate of Salvianic acid A (HY-N1913). Salvianic acid A, an orally active phenolic compound, can induce Nrf2/HO-1 activation and inhibition of NF-κB pathway. Danshensu has anti-oxidation, anti-apoptosis, anti-lung inflammatory and has the potential for COVID-19, cardiovascular and cerebrovascular diseases research .
    (Rac)-Salvianic acid A
  • HY-108744
    Pitavastatin magnesium

    		HMG-CoA Reductase (HMGCR) Cardiovascular Disease
    Pitavastatin magnesium is an orally active HMG-CoA Reductase inhibitor. Pitavastatin magnesium lowers total cholesterol and low-density lipoprotein cholesterol in a hyperlipidemic rat model. Pitavastatin magnesium can be used in research on cardiovascular and cerebrovascular diseases such as hyperlipidemia .
    Pitavastatin magnesium
  • HY-120960
    N-Arachidonoyl-L-serine

    ARA-S

    		 Akt p38 MAPK Apoptosis Potassium Channel Cardiovascular Disease Neurological Disease
    N-Arachidonoyl-L-serine (ARA-S) is an endocannabinoid. N-Arachidonoyl-L-serine induces phosphorylation of Akt and MAPK in endothelial cells. N-Arachidonoyl-L-serine also induces endothelium-dependent vasodilation in isolated rat mesenteric and abdominal aortas. N-Arachidonoyl-L-serine exhibits neuroprotective effects after traumatic brain injury by reducing apoptosis. N-Arachidonoyl-L-serine promotes the opening of KV7.1/KCNE1 channels in mammalian cells and shortens the action potential duration in cardiomyocytes. N-Arachidonoyl-L-serine may be used in research on cardiovascular and cerebrovascular diseases and neurological disorders .
    N-Arachidonoyl-L-serine
  • HY-N5078
    Terrestrosin K

    		Others Cardiovascular Disease
    Terrestrosin K, a steroidal saponin from Tribulus terrestris L., has potential to treat cardiovascular and cerebrovascular diseases .
    Terrestrosin K
  • HY-164014
    9-CCN

    		Autophagy Cardiovascular Disease
    9-CCN is a lipid compound that specifically targets macrophages. 9-CCN can be used in the study of cardiovascular and cerebrovascular diseases .
    9-CCN
  • HY-N13380
    6′‐O‐Galloylsalidroside

    		Others Cardiovascular Disease Neurological Disease Metabolic Disease
    6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases .
    6′‐O‐Galloylsalidroside
  • HY-124229
    PD 122860

    		Sodium Channel Calcium Channel Cardiovascular Disease
    PD 122860 is a calcium channel blocker. PD 122860 also can stimulate sodium channel. PD 122860 can be used for the research of cardiovascular and cerebrovascular diseases .
    PD 122860
  • HY-P2749
    Glutamine synthetase

    		Biochemical Assay Reagents Cardiovascular Disease Cancer
    Glutamine synthetase is an enzyme that converts glutamate and ammonia into glutamine. Glutamine synthetase can inhibit angiogenesis in ocular and inflammatory skin diseases. Glutamine synthetase can also palmitoylate RHOJ, thereby inhibiting endothelial cell migration. Glutamine synthetase can be used in research on various diseases, including cardiovascular and cerebrovascular diseases and cancer .
    Glutamine synthetase
  • HY-119512
    Ethoxomane

    Ethomoxane

    		 Adrenergic Receptor Cardiovascular Disease
    Ethoxomane (Ethomoxane) is an α-adrenergic receptor blocker. Ethoxomane elevates the hissing threshold induced by perifornical hypothalamic stimulation in cats. Ethoxomane exhibits antihypertensive effects. Ethoxomane can be used in the research of cardiovascular and cerebrovascular diseases .
    Ethoxomane
  • HY-19013
    L 44-0

    		Drug Derivative Cardiovascular Disease
    L44-0 is a nicotinic acid derivative. L44-0 reduces atherosclerotic lesions and decreases vascular norepinephrine levels in the renal arteries, femoral arteries, and veins in a New Zealand white rabbit model of atherosclerosis. L44-0 can be used in research on cardiovascular and cerebrovascular diseases such as atherosclerosis .
    L 44-0
  • HY-121765R
    Dacisteine (Standard)

    N,S-Diacetyl-L-cysteine (Standard)

    		 Reference Standards Endogenous Metabolite Metabolic Disease
    Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
    Dacisteine (Standard)
  • HY-19089
    DPN-205-734

    		Phosphodiesterase (PDE) Cardiovascular Disease
    DPN-205-734 is an orally administered cGMP-PDE inhibitor. DPN-205-734 exhibits positive inotropic effects in various animal cardiomyocytes. DPN-205-734 reduces blood pressure and total peripheral resistance in multiple animal models, demonstrating a debulking effect. DPN-205-734 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure .
    DPN-205-734
  • HY-128393S1
    Trilinolein-13C54

    		Isotope-Labeled Compounds PI3K Akt E-Selectin Apoptosis MMP MEK ERK Cancer
    Trilinolein- 13C54 is the 13C-labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .
    Trilinolein-13C54
  • HY-128393R
    Trilinolein (Standard)

    		Reference Standards PI3K Akt E-Selectin Apoptosis MMP MEK ERK Cancer
    Trilinolein (Standard) is the analytical standard of Trilinolein (HY-128393). This product is intended for research and analytical applications. Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .
    Trilinolein (Standard)
  • HY-14474
    CGS 26303

    		Endothelin-Converting Enzyme (ECE) Cardiovascular Disease
    CGS 26303 is an endothelin-converting enzyme (ECE) inhibitor. CGS 26303 increases the expression of endothelin-converting enzyme-1 in endothelial cells. CGS 26303 attenuates cerebral vasospasm in a rabbit subarachnoid hemorrhage model. CGS 26303 improves birth survival and alleviates pulmonary hypoplasia in newborn rats in a rat model of congenital diaphragmatic hernia. CGS 26303 can be used for research on cardiovascular and cerebrovascular diseases and congenital diaphragmatic hernia .
    CGS 26303
  • HY-B0531S
    Triflusal-d3

    		Isotope-Labeled Compounds COX NF-κB Phosphodiesterase (PDE) NO Synthase Prostaglandin Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
    Triflusal-d3
  • HY-168770
    Cl-Necrostatin-1

    		RIP kinase TNF Receptor Apoptosis Cardiovascular Disease
    Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC50 = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases .
    Cl-Necrostatin-1
  • HY-B0531R
    Triflusal (Standard)

    		Reference Standards COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Triflusal (Standard) is the analytical standard of Triflusal (HY-B0531). This product is intended for research and analytical applications. Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
    Triflusal (Standard)
  • HY-123864
    SC-68448

    S 448

    		 Integrin Cardiovascular Disease Cancer
    SC-68448 (S 448) is a selective αvβ3 antagonist (IC50 = 1 nM). SC-68448 inhibits αvβ3-mediated endothelial cell proliferation. SC-68448 reduces the total level of αvβ6 in NHBE cells. SC-68448 inhibits angiogenesis in a rat corneal neoplasia model. SC-68448 inhibits tumor growth and completely prevents the development of hypercalcemia in a rat Ledich cell tumor model. SC-68448 can be used in research on cardiovascular and cerebrovascular diseases such as hypercalcemia and cancers such as testicular interstitial cell tumors .
    SC-68448
  • HY-108291
    Propatyl nitrate

    		Others Cardiovascular Disease
    Propatyl nitrate is a coronary vasodilator. Propatyl nitrate is also a nitric oxide donor. Propatyl nitrate can be used in research on cardiovascular and cerebrovascular diseases such as acute angina attacks .
    Propatyl nitrate
  • HY-19091
    ICI-170777

    		Adrenergic Receptor Cardiovascular Disease
    ICI-170777 is an orally active cardiotonic agent. ICI-170777 enhances cardiac contractility and induces arteriovenous dilation in animal models of congestive heart failure. ICI-170777 can be used in research on cardiovascular and cerebrovascular diseases such as heart failure .
    ICI-170777
  • HY-181436
    CAY10563

    		NO Synthase Cardiovascular Disease
    CAY10563 is a pH-regulated NO donor. Under acidic conditions, CAY10563 releases NO via an acid-catalyzed ring-opening mechanism, generating sulfur-centered free radicals. CAY10563 induces pH-dependent vasodilation. CAY10563 can be used in studies related to cardiovascular and cerebrovascular diseases .
    CAY10563
  • HY-N16538
    4-(Acetoxymethyl)phenyl glucoside

    		Drug Derivative Cardiovascular Disease Neurological Disease
    4-(Acetoxymethyl)phenyl glucoside is a type of gastrodin derivative that can cross the blood-brain barrier. 4-(Acetoxymethyl)phenyl glucoside exhibits sedative, anticonvulsant and analgesic effects in mouse models. 4-(Acetoxymethyl)phenyl glucoside can be used for research on senile cardiovascular and cerebrovascular diseases as well as brain nerve disorders .
    4-(Acetoxymethyl)phenyl glucoside
  • HY-128393S2
    Trilinolein-d5

    		Isotope-Labeled Compounds PI3K Apoptosis ERK MMP Akt MEK E-Selectin Cancer
    Trilinolein-d5 is the deuterium labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .
    Trilinolein-d5
  • HY-180322
    TG2-IN-3h

    		Glutaminase Cardiovascular Disease Metabolic Disease
    TG2-IN-3h (Compound 3h) is a transglutaminase (TG2) inhibitor (hTG2: IC50 = 6nM). TG2-IN-3h inhibits endothelial cell migration and angiogenesis. TG2-IN-3h alleviates renal fibrosis in a mouse model of hypertensive nephropathy. TG2-IN-3h can be used in research on metabolic diseases such as hypertensive nephropathy and cardiovascular and cerebrovascular diseases such as pathological angiogenesis .
    TG2-IN-3h
  • HY-175068
    D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium

    Ins(1,3,4,5,6)P5 sodium

    		 PI3K Akt Apoptosis Cardiovascular Disease Cancer
    D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium (Ins(1,3,4,5,6)P5 sodium) is a small intracellular signaling molecule. D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium inhibits the PI3K/Akt signaling pathway. D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium inhibits Akt/PKB phosphorylation and kinase activity, inducing apoptosis in cancer cells. D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium inhibits the formation of tubular structures in endothelial cells in an in vitro angiogenesis mouse model. D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium can be used in research on ovarian cancer, lung cancer, breast cancer, and other cancers, as well as in cardiovascular and cerebrovascular diseases such as angiogenesis .
    D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: